Form 8-K - Current report:
SEC Accession No. 0001140361-22-034294
Filing Date
2022-09-21
Accepted
2022-09-21 16:31:52
Documents
13
Period of Report
2022-09-15
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ny20005291x2_8k.htm   iXBRL 8-K 53291
  Complete submission text file 0001140361-22-034294.txt   239797

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA roiv-20220915.xsd EX-101.SCH 4630
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE roiv-20220915_def.xml EX-101.DEF 18286
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE roiv-20220915_lab.xml EX-101.LAB 28479
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE roiv-20220915_pre.xml EX-101.PRE 20528
7 EXTRACTED XBRL INSTANCE DOCUMENT ny20005291x2_8k_htm.xml XML 6756
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11 D0 HM11 441-295-5950
Roivant Sciences Ltd. (Filer) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-40782 | Film No.: 221256734
SIC: 2834 Pharmaceutical Preparations